Trump threatens 50% tariffs on Brazil if it doesn't stop the Bolsonaro 'witch hunt' trial    Trump praises 'good English' of Liberian president, prompting criticism across Africa    Saudi, Hungarian defense ministers discuss military ties    Al-Rajhi: Cabinet's decision is supportive to most vulnerable groups    King Salman appoints Dr. Majid Al-Fayyad as Royal Court advisor    Alkhorayef emphasizes Saudi Arabia's growing role as global industrial investment hub    Saudi Arabia adopts World Drowning Prevention Day as national health priority    GACA imposes SR2.8 million in fines for 87 civil aviation violations in Q2 2025    Desperate Gaza doctors cram several babies into one incubator as fuel crisis reaches critical point    Total e-messages sent to parties in lawsuits reach over 11.8 million during first half of 2025    3 arrested in assault case in Riyadh    New Property Ownership Law will take into effect in January 2026 Al-Hogail thanks King and Crown Prince for the updated law    HONOR returns to Esports World Cup as Official Smartphone Partner for 2025 The renewed commitment will see HONOR elevate mobile esports competition with cutting-edge AI technologies and industry-leading hardware    Riot Games responds to match-fixing allegations in VALORANT    BLAST responds to BESTIA Visa controversy ahead of CS2 Austin major    Christophe Galtier named NEOM SC head coach ahead of historic Saudi Pro League debut    Michael Madsen, actor of 'Kill Bill' and 'Reservoir Dogs' fame, dead at 67    BTS are back: K-pop band confirm new album and tour    Michelin Guide launches in Saudi Arabia with phased rollout in 2025    'How fragile we are': Roskilde Festival tragedy remembered 25 years on    Sholay: Bollywood epic roars back to big screen after 50 years with new ending    Ministry launches online booking for slaughterhouses on eve of Eid Al-Adha    Shah Rukh Khan makes Met Gala debut in Sabyasachi    Pakistani star's Bollywood return excites fans and riles far right    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



KIDNEY CANCER GETS NEW DRUGS
Published in Saudi Press Agency on 04 - 06 - 2006

FOR THE FIRST TIME IN DECADES THERE ARE NEW TREATMENTS AVAILABLE FOR KIDNEY CANCER, AND AS MORE DATA EMERGES ABOUT THEIR EFFICACY, THE COMPETITION LOOKS SET TO HEAT UP, REUTERS REPORTED.
DATA PRESENTED ON SUNDAY AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONFIRMED THE POTENCY OF SUTENT, A DRUG MARKETED BY PFIZER INC. THAT WAS APPROVED BY U.S. REGULATORS IN JANUARY.
FOR THE FIRST TIME, TOO, DATA WAS RELEASED FROM A LATE-STAGE, OR PHASE III, CLINICAL TRIAL OF AN EXPERIMENTAL NEW DRUG FROM WYETH CALLED TEMSIROLIMUS THAT SHOWED IT IMPROVED OVERALL SURVIVAL BY 49 PERCENT IN PATIENTS WITH THE POOREST OUTLOOK.
NEXAVAR, A DRUG MADE BY ONYX PHARMACEUTICALS INC. AND BAYER AG, WAS APPROVED IN DECEMBER AND HAS ALREADY SHOWN THAT IT DOUBLED THE TIME BEFORE THE DISEASE PROGRESSED TO 24 WEEKS FROM 12 WEEKS FOR PATIENTS IN THE PLACEBO GROUP.
ON MONDAY, INVESTIGATORS WILL RELEASE UPDATED SURVIVAL DATA FOR NEXAVAR. THIS TIME LAST YEAR, INTERIM RESULTS OF A PHASE III TRIAL SHOWED THAT NEXAVAR IMPROVED SURVIVAL BY 39 PERCENT, BUT THE RESULTS WERE NOT STATISTICALLY SIGNIFICANT.
WHILE TRIAL INVESTIGATORS FOR SUTENT AND TEMSIROLIMUS EACH CLAIMED SUPERIORITY FOR THEIR DRUG, THEY CONCEDED THAT DIRECT COMPARISONS WERE IMPOSSIBLE AS EACH TRIAL WAS DESIGNED DIFFERENTLY. THE SUTENT TRIAL, FOR EXAMPLE, TESTED PATIENTS WITH A WIDE RANGE OF DISEASE SEVERITY, FROM THOSE WHOSE PROGNOSIS WAS FAVORABLE TO THOSE WHOSE PROGNOSIS WAS POOR. ABOUT 40 PERCENT WERE IN THE MIDDLE.
THE LATE-STAGE CONFIRMATORY TRIAL OF SUTENT SHOWED THE MEDIAN TIME BEFORE WHICH A PATIENT'S DISEASE PROGRESSED WAS 11 MONTHS IN THE SUTENT GROUP COMPARED TO FIVE MONTHS IN THE GROUP TAKING STANDARD INTERFERON THERAPY. THE RESPONSE RATE, A MEASURE OF TUMOR SHRINKAGE, WAS 31 PERCENT IN THE SUTENT GROUP COMPARED TO 6 PERCENT IN THE INTERFERON GROUP.
THE RESULTS DID NOT SHOW WHETHER PATIENTS WHO TOOK SUTENT LIVED LONGER THAN THOSE WHO TOOK THE STANDARD THERAPY.
WYETH, BY CONTRAST, ONLY TESTED PATIENTS WITH THE POOREST PROGNOSIS. ITS TRIAL FOUND PATIENTS WHO WERE TREATED WITH TEMSIROLIMUS ALONE HAD A MEDIAN SURVIVAL TIME OF 10.9 MONTHS, COMPARED WITH 7.3 MONTHS IN THE INTERFERON GROUP.
"IN GENERAL, IN ONCOLOGY, DRUGS THAT WORK IN PATIENTS WITH THE WORST PROGNOSIS WILL WORK AT LEAST AS WELL IF NOT BETTER IN THOSE WITH A BETTER PROGNOSIS," SAID GARY HUDES, DIRECTOR OF THE GENITOURINARY MALIGNANCIES PROGRAM AT FOX CHASE CANCER CENTER IN PHILADELPHIA.
THE WYETH DRUG, WHICH HAS NOT YET BEEN APPROVED, IS IMPORTANT BECAUSE IT IS THE FIRST TO FULLY VALIDATE THE POTENTIAL OF A NEW TARGET FOR CANCER THERAPY CALLED MTOR, HUDES SAID. MTORIS A SIGNALING PROTEIN THAT REGULATES CELL AND BLOOD VESSEL GROWTH.


Clic here to read the story from its source.